Pharmaco-epidemiological Study on the Effect of Retacrit on Chemotherapy Induced Anaemia in Standard Oncology and Haematology Practice: Impact of Concomitant Iron Supplementation

Trial Profile

Pharmaco-epidemiological Study on the Effect of Retacrit on Chemotherapy Induced Anaemia in Standard Oncology and Haematology Practice: Impact of Concomitant Iron Supplementation

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Epoetin zeta (Primary)
  • Indications Chemotherapy-induced anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SYNERGY
  • Sponsors Hospira
  • Most Recent Events

    • 11 Jul 2016 New source identified and integrated ClinicalTrials.gov: US National Institutes of Health: (NCT02158169)
    • 07 Jun 2016 Results of sub-analysis of patients with hematological malignancies (n=423) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results (subanalysis, n = 1657) assessing efficacy of epoetin zeta in patients with solid tumors presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top